| Literature DB >> 25427572 |
Sai Li1, Xiao-Hong Su2, Wen-Jing Le3, Fa-Xing Jiang4, Bao-Xi Wang5, Peter A Rice6.
Abstract
BACKGROUND: Evolving gonococcal antimicrobial resistance (AMR) poses a serious threat to public health. The aim of this study was to: update antimicrobial susceptibility data of Neisseria gonorrhoeae recently isolated in Nanjing, China and identify specific deteminants of antimicrobial resistance and gentoypes of isolates with decreased sensitivity to ceftriaxone.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25427572 PMCID: PMC4263019 DOI: 10.1186/s12879-014-0622-0
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
antimicrobial susceptibility of : clinical isolates (n = 334)
| Antimicrobial breakpoints (susceptible/resistant [mg/L]) a | No. (%) | MIC (mg/L) | ||||
|---|---|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | Range | MIC 50 | MIC 90 | |
| Penicillin G (S ≤ 0.06/R ≥ 2) | 0 | 108 (32.3) | 226 (67.7) | 0.125 to >8 | 2 | >8 |
| Tetracycline (S ≤ 0.25/R ≥ 2) | 2 (0.6) | 5 (1.5) | 327 (97.9) | 0.25 to >16 | 8 | >16 |
| Ciprofloxacin (S ≤ 0.06/R ≥ 1) | 0 | 4 (1.2) | 330 (98.8) | ≤0.25 to >8 | >8 | >8 |
| Spectinomycin (S ≤ 32/R ≥ 128) | 334 (100) | 0 | 0 | ≤4 to 32 | 16 | 32 |
| Ceftriaxone (S ≤ 0.25) | 334 (100) | - | - | 0.004 to 0.25 | 0.03 | 0.06 |
aAntimicrobial breakpoints that distinguish susceptible from resistant gonococcal isolates (CLSI Document M07-A9 (M100-S22) [35]. MIC: minimum inhibitory concentration.
Distribution of β-lactamase-encoding and -encoding plasmids: clinical isolates (n = 334)
| Type of | Type of β-lactamase producing plasmid | ||
|---|---|---|---|
| Asian/New Zealand | African/Nîmes | β-lactamase negative | |
| Dutch | 46 | 0 | 54 |
| American | 0 | 3 | 1 |
|
| 62 | 9 | 159 |
Genetic characteristics of with increased MICs (n = 15) to ceftriaxone (≥0.125 mg/L)
| Isolate no. | Ceftriaxone MICs (mg/L) | Antimicrobial characteristics | NG-MAST | PBP2 allele | Polymorphisms in: | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| porB | tbpB | STs | MtrR | PorB1b | PBP1 | PilQ | ||||
| NJ-1 | 0.25 | CMRNG, CipR# | 5658 | 111 | 9530* | XVIII | −57A del, A39T | G120K, A121D | L421P | wt |
| NJ-2 | 0.25 | CMRNG, CipR | 5175 | 328 | 8737 | XVIII | −57A del, A39T | G120K, A121D | L421P | wt |
| NJ-3 | 0.125 | PPNG, CipR | 5659 | 107 | 9531* | XVIII | −57A del | G120K, A121G | L421P | wt |
| NJ-4 | 0.125 | PP/TRNG, CipR | 1053 | 186 | 3289 | XVIII | −57A del | G120K, A121D | L421P | wt |
| NJ-5 | 0.125 | PPNG, CipR | 1854 | 33 | 9532* | XLI** | −57A del | G120N, A121D | L421P | wt |
| NJ-6 | 0.125 | PP/TRNG, CipR | 543 | 294 | 9533* | XVIII | A39T | G120K, A121G | L421P | wt |
| NJ-7 | 0.125 | CMRNG, CipR | 5660 | 186 | 9534* | XVIII | −57A del | G120K, A121G | L421P | wt |
| NJ-8 | 0.125 | CMRNG, CipR | 505 | 135 | 2186 | XVIII | −57A del | G120K, A121D | L421P | wt |
| NJ-9 | 0.125 | CMRNG, CipR | 1285 | 4 | 9535* | XIII | −57A del, G45D | G120K, A121D | L421P | wt |
| NJ-10 | 0.125 | TRNG, CipR | 4 | 831 | 3746 | XIII | −57A del | G120K, A121D | L421P | wt |
| NJ-11 | 0.125 | CMRNG, CipR | 3530 | 4 | 9536* | XVIII | −57A del | G120K, A121G | L421P | wt |
| NJ-12 | 0.125 | CMRNG, CipR | 1198 | 156 | 2461 | XVIII | −57A del, A39T | G120K, A121G | L421P | wt |
| NJ-13 | 0.125 | CMRNG, CipR | 5661 | 4 | 5061 | XVIII | −57A del, G45D | G120K, A121N | L421P | wt |
| NJ-14 | 0.125 | CMRNG, CipR | 2978 | 1058 | 9537* | XII | −57A del | G120K, A121D | L421P | wt |
| NJ-15 | 0.125 | TRNG, CipR | 543 | 438 | 9538* | XVIII | −57A del | G120K, A121G | L421P | wt |
wt, wild type.
*New NG-MAST STs detected in this study.
**A new PBP2 allele previously not identified was named XLI according to previously used Nomenclature.
#isolates exhibiting resistance to ciprofloxacin (MIC ≥ 1 mg/L).
Figure 1Distribution of ceftriaxone MICs of isolates: Nanjing, 2006 (n = 198) and 2011–12 (n = 334).
Figure 2Distribution of spectinomycin MICs of isolates: Nanjing, 2006 (n = 198) and 2011–12 (n = 334).